Home Contact

logo

Family

Links:






Archives:


Newsletter:

Register for our Free monthly newsletter to receive timely updated information about Parkinsons Disease directly in your email.
Email
First Name
Last Name
Zip Code

Categories:



Register for our FREE monthly newsletter to receive timely updated information about Parkinsons Disease directly in your email.

Archive for October, 2007

Rotigotine, Also Known As Neupro Combats Restless Leg Syndrome As Well As Parkinson’s Disease

Wednesday, October 10th, 2007

Recently I have learned about a syndrome that in some ways relates to Parkinson’s disease called Restless Leg Syndrome (RSL). RLS is not to be confused with bouncy legs that many people do they may be nervous or impatient, but it is more of a very uncomfortable feeling in the legs, arms, or torso.  Relief comes when movement is made. Because we’ve recently learned what RLS is there are still a lot of things we don’t know about it. One recent finding is that Rotigotine a drug originally produced for those suffering from Parkinson’s disease has also been proven to greatly reduce the discomfort in RLS.

Currently Rotigotine, and more famously known as Neupro, is a drug that is delivered via a patch, much like the nicotine patches that have become so famous. The patch’s purpose is to deliver the drug in a slow and constant form over a twenty-four hour period. Many people have expressed great interest in Neupro because it beats taking a bunch of pills a couple of times a day, in the patches case you just have to apply to the skin and for the next 24 hours you’re good to go. It sounds great but there are also some possible side-effects and other determinants (as with all drugs) to its use. Some side-effects that have been reported are: skin reactions at the patch site, dizziness, nausea, vomiting, drowsiness and insomnia. Other determinants would be the discomfort the patch may have on the skin and even the possibility of it getting ripped off.

Neupro(R) (Rotigotine Transdermal System) is currently approved in the United States for the treatment of early-stage idiopathic Parkinson’s disease and in Europe for the treatment of patients with early-stage Parkinson’s disease and in combination with levodopa for advanced-stage Parkinson’s disease. Applications for the use of rotigotine transdermal system in patients with moderate-to-severe RLS are currently being prepared for submission to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMEA).

Avid Begins Phase I Trials for a Compound that treats Lewy Bodies and Parkinson’s Disease

Tuesday, October 9th, 2007

Avid has just announced that it will begin phase I trials for its new compound. The compound will be tested on 30 volunteers. Avid’s compound By bindsto the VMAT2 transporter, Avid’s (18)F-AV-133 compound can image neuronal loss in the brain, making it a potentially effective biomarker for earlier detection and diagnosis of these diseases. In short it basically releases a compound that link to dementia transporters which can be tracked to find if a dementia related disease may be on the horizon. Dementia related diseases include Parkinson’s disease, Alzheimer’s disease, Lewy Body disease and other dementia related diseases.

Avid’s compound may also be a possibility in treating Alzheimer’s, but right now it is being tested only as a detector for dementia related diseases. We will keep our subscribers updated as this trial gains more substance.

Couple Face Parkinson’s Disease Together

Tuesday, October 9th, 2007

SCARBOROUGH (Oct 5, 2007): Scott and Lisa Norton always felt very fortunate. Three years ago, just days before celebrating their 25th wedding anniversary, the Scarborough couple were first faced with their biggest hurdle. After being referred to a specialist for what Scott thought to be a pinched nerve in his left shoulder, he came home with a diagnosis that would change his life. At only 48 years old, he had Parkinson’s disease.

“He told me right then and there. It was quite a blow,” Scott Norton said about receiving the diagnosis on his first visit to a specialist.

According to Lillian Scenna, of the Parkinson’s Information and Referral Center in Falmouth, Norton is one of 1.5 million Americans and an estimated 7,000 Mainers with the illness, which kills nerve cells in the brain, causing impaired muscle function. Though the majority of patients are diagnosed after the age of 65, 15 percent are diagnosed before they turn 50 and some as early as 30. Like many neurological disorders, there is no blood test to prove someone has Parkinson’s. Specialists must determine visually whether a patient has the disease.

When symptoms progress significantly, patients may be in need of a constant caregiver. On Nov. 2, the Maine Parkinson Society is holding a silent and live auction to raise money to help patients pay for respite care, which is outside assistance that provides temporary relief for caregivers.

This year’s auction chairwoman, Jamie Crain of South Portland, became involved with the auction when her father, Rick Dobson, also of South Portland, was diagnosed with Parkinson’s three years ago at the age of 58.

“We didn’t know anything about Parkinson’s until he was diagnosed,” said Crain, 30. “All of a sudden, it changes your whole future.”

Though Crain said she didn’t know what to expect, by talking with other families who were dealing with the same experience, she learned a lot. She said her father, who is the president of Consumer Credit Counseling Services of Maine, still works full-time and isn’t even taking medication.

According to Scenna, the most difficult part for most patients is an inability to communicate their needs.

“There’s a very intelligent person in there,” Scenna said. Due to symptoms like tremors, slow movement and stiffness of the muscles, patients have a hard time communicating both with speech and facial expressions.

Though Norton was shocked to receive his initial diagnosis, his wife said, after they knew what was wrong, things started to add up. Soon, they noticed he was moving slower and talking softer. Scott Norton said he felt a very soft tremor in his left hand. He had developed a “Parkinson’s mask,” meaning his face was stiff and expressionless. Now, with medication, he can smile again.

“After he was diagnosed, it was, ‘Oh, that makes sense,’” Lisa Norton said about noticing symptoms.

Still, Scott Norton said it took about two months for the diagnosis to sink in for him.

“As we got comfortable with the diagnosis – just being able to say it – we started telling friends,” Lisa Norton said. Though she knows some Parkinson’s patients who prefer to keep their condition under wraps, Norton said everyone her husband knows is aware of his illness, and the support has been incredible. As Lisa Norton prepares to travel, she knows friends will be by their Scarborough home constantly checking up on him and seeing whether there is anything they can do to help.

But Scott Norton is far from dependent. The truck-part salesman, now 51, continues to work. Though he stays at home more, he has become a great househusband, according to his wife, who boasts about his laundry skills.

Lisa Norton has taken on a new task, as well. For the past year and a half, Norton, who works in advertising and sales for the Portland Radio Group, has served on the board of the Maine Parkinson Society.

Though Norton said she was initially obsessive about reading up on and keeping track of Parkinson’s research, she has learned to sit back and enjoy life as it comes. Now, she is hoping to help educate others about the illness, which, she believes, with the baby boomer generation getting into their 50s and 60s, will be a lot more prevalent in the country in the coming years.

Scenna said that though the illness is most common in older people, one of the least known facts about the disease is that people can be diagnosed as early as 30.

“When people think of Parkinson’s, they think of grandparents, Muhammed Ali and Michael J. Fox,” Lisa Norton said.

Scenna said having someone in the public eye who developed Parkinson’s at a young age, like Fox, has been instrumental in getting the word out.

The rate of progression of the disease varies from person to person, but can advance to the point where a patient is bound to a wheelchair. According to Scenna, patients don’t die from Parkinson’s disease, they die with Parkinson’s disease. However, complications from the symptoms can lead to death.

“When you hear somebody has this condition, you fast forward,” Norton said.

Norton worries about her 18-year-old son, Nicholas, too. Though it is unknown exactly how people develop Parkinson’s, there is sometimes, but rarely, a family history of the illness, as well as a loose association with drinking well water. Norton said her family has stopped drinking the tap water at their home as a precaution. However, she said, even if there is a hereditary component, she knows in 20 years, when her son might be at risk, treatment will have advanced significantly.

“I see hope on the horizon,” Scenna said. “Just in the past 10 years, we’ve learned so much about Parkinson’s.”

Scenna remembers when her grandfather was diagnosed with the disease, there was only one medication he could take.

“If he were alive today, he wold have had a host of options,” she said.

For Scott Norton, the most difficult part of the disease is the constant reminder that he has it.

“It’s always on your mind, everything you do,” he said. His wife said she has worked hard not to let it consume her life, though it has certainly changed it significantly.

“It really puts into perspective, without sounding cliche, to live for now,” she said. “Live each day.”

A Closer Look
An Evening of Hope, a benefit auction for the Maine Parkinson Society, will be held Friday, Nov. 2, 5:30-9 p.m. at The Woodlands Club, Falmouth. For tickets, go to www.maineparkinsonsociety.org or call 1-800-832-4116.


 

Isradapine A Treatment for Parkinson’s Disease

Wednesday, October 3rd, 2007

dynacirccr5.gif A few different drugs have been able to cross over and treat two different diseases at the same time.  Evista, a drug for post-menopausal women for the treatment of osteoporosis has now been found to greatly decrease the risk of breast cancer.  Such a feat has now been duplicated with Parksinson’s disease with the drug Isradapine.

Isradapine is a drug that is a calcium-blocker that is marketed in Britain by Novartis as Prescal for the control of high blood pressure.  Isradapine can correct the underlying problem in Parkinson’s: the failure of brain cells to make dopamine.

Time reports of a recent study that proves Isradapine’s efficacy, ”In Nature online, a team led by James Surmeier reported that mice with a disease related to Parkinson’s were rejuvenated by doses of isradipine. Tests showed that the mice, which had been genetically engineered to have a Parkinson’s-like disease, resisted becoming ill and their dopamine-producing cells began to function as if they were younger. If the same was found to be true in human patients it could be a big advance in managing the disease.”

Researchers hope that with further research and trials that Isradapine can be proven to help halt Parkinson’s disease like baby aspirin can halt heart disease.  As more information become available we’ll report on it, keep in touch. 

Depression Common in Parkinson’s Disease

Tuesday, October 2nd, 2007

Sept. 29, 2004 — Depression affects almost half of all people with Parkinson’s disease, says a University of Rochester neurologist.

The depression isn’t a dismayed reaction to Parkinson’s disease. Rather, it’s part of the illness, says Irene Richard, MD, of the University of Rochester Medical Center in Rochester, N.Y.

Parkinson’s disease affects brain cells called the substantia nigra, which produce the chemical dopamine. Dopamine helps control movement; when levels of the chemical are substantially reduced, movements get garbled.

Parkinson’s disease also affects cells that produce brain chemicals such as serotonin and norepinephrine, which can play a role in depression, according to a University of Rochester news release.

Approximately 1 million Americans have Parkinson’s disease. It’s usually diagnosed in people age 50 or older, although it’s sometimes found in people in their 30s and 40s. The cause is unknown.

“The depression is part of the illness, not simply a reaction to the disease,” says Richards in the news release.

Of depressed Parkinson’s disease patients, about half have “major” depression that significantly affects their lives. Others have milder symptoms, which are still serious.

Mood and Movement Disorders

Other research shows there may be a link between depression and movement disorders.

Richards and Emory University psychiatrist William McDonald, MD, recently wrote about the possible connection in the journal Neurology.

The pair reviewed a study about depression and a painful involuntary movement disorder called dystonia.

The study, by Gary Heiman, PhD, of Columbia University, and colleagues focused on a mutation of the dystonia gene DYT1.

Heiman’s team found that people with a mutated DYT1 gene had increased risk for recurrent major depression. They say that the depressive disorder in these people occurs at an earlier age than people without the gene mutation. They say depression is not the result of having dystonia.

Heiman’s study was small, but Richards and McDonald say if larger studies confirm the findings, it could point to a link between disorders of movement and mood.

Solutions Sought

Richards and McDonald are leading a national study to test the effectiveness of the antidepressants Paxil and Effexor in Parkinson’s disease patients.

People with Parkinson’s disease may respond differently to the medications than other people, since the disease affects their brains.

Meanwhile, Richards encourages Parkinson’s patients to discuss depression with their doctors.

“Many patients assume that it’s normal to feel this way,” she says. “They might say, ‘If you had Parkinson’s disease, you’d feel this way too.’ That’s not true.”

“If you treat the depression, they’ll still have other symptoms of the disease, but they feel better. It’s one aspect of the disease that may be very treatable.”

source: WebMD

EU Approves Exelon Patch for Parkinson’s Disease

Monday, October 1st, 2007

The European Union have just approved Exelon’s patch for Alzheimer’s disease. The patch has been a paramount discovery for many people, one being the great down sizing of pills. The frequency of pills, sometimes taking them 3 or 4 times a day, or other types of treatment can decline because of the patch. Although 3 or 4 times may not sound like a lot, it can become a nuisance at work, at church, on vacation, or simply spending time with family and friends. A new way for PD sufferers to take their drug treatments has been approved by the FDA–a patch.”James Papadakis was two years into his battle with Parkinson’s disease and his symptoms had taken a turn for the worse when his Baylor College of Medicine doctor suggested an experimental new skin patch back in 2002.

Instead of taking pills three or four times a day, he could just apply one of the patches once a day and it would supply medication continuously over the 24 hours.

It’s easy to put on, it’s more effective and it’s once a day. You don’t have to worry whether you took all your pills … There’s really no downside.”

The patch can be applied anywhere on the body and lasts up to 24 hours.